Critical Survey: Sight Sciences (NASDAQ:SGHT) and Merit Medical Systems (NASDAQ:MMSI)

Sight Sciences (NASDAQ:SGHTGet Free Report) and Merit Medical Systems (NASDAQ:MMSIGet Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Risk and Volatility

Sight Sciences has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Sight Sciences and Merit Medical Systems, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sight Sciences 0 5 2 0 2.29
Merit Medical Systems 0 1 8 1 3.00

Sight Sciences currently has a consensus price target of $3.92, indicating a potential upside of 19.78%. Merit Medical Systems has a consensus price target of $108.67, indicating a potential upside of 10.77%. Given Sight Sciences’ higher probable upside, research analysts plainly believe Sight Sciences is more favorable than Merit Medical Systems.

Earnings and Valuation

This table compares Sight Sciences and Merit Medical Systems”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sight Sciences $78.11 million 2.16 -$55.55 million ($0.98) -3.34
Merit Medical Systems $1.39 billion 4.18 $94.41 million $2.04 48.09

Merit Medical Systems has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sight Sciences and Merit Medical Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sight Sciences -63.30% -47.28% -32.72%
Merit Medical Systems 9.05% 15.61% 8.38%

Institutional & Insider Ownership

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by insiders. Comparatively, 3.2% of Merit Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Merit Medical Systems beats Sight Sciences on 12 of the 15 factors compared between the two stocks.

About Sight Sciences

(Get Free Report)

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

About Merit Medical Systems

(Get Free Report)

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.